Tarsus Pharmaceuticals, Inc. SEC filings TARS

Tarsus Pharmaceuticals, Inc. has 676 filings in SEC EDGAR's recent list, going back to Aug 7, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.

Tarsus Pharmaceuticals, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Nov 3, 2026 Sep 30, 2026
8-K Current report
Results of operations
Nov 3, 2026 Nov 3, 2026
S-3ASR Automatic shelf registration Oct 13, 2026 —
S-3ASR Automatic shelf registration Oct 13, 2026 —
8-K/A Amended current report Oct 13, 2026 Sep 4, 2026
8-K Current report
Acquisition or sale of assets, Other events
Sep 10, 2026 Sep 4, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 6, 2026 Aug 6, 2026
8-K Current report
Material agreement, Unregistered share sale, Other events
Aug 6, 2026 Aug 5, 2026
8-K Current report
Material agreement, Unregistered share sale, Other events
Aug 6, 2026 Jul 31, 2026
8-K Current report
Officer or director change
Jul 13, 2026 Jul 13, 2026
8-K Current report
Material agreement, Unregistered share sale, Other events
Jul 8, 2026 Jul 6, 2026
8-K Current report
Shareholder vote results
Jun 29, 2026 Jun 25, 2026
10-Q Quarterly report May 6, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 6, 2026 May 6, 2026
ARS Annual report to shareholders Apr 28, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 25, 2026
S-8 Employee stock plan registration Feb 23, 2026 —
10-K Annual report Feb 23, 2026 Dec 31, 2025
8-K Current report
Results of operations
Feb 23, 2026 Feb 23, 2026
8-K Current report
Officer or director change
Feb 18, 2026 Feb 18, 2026
8-K Current report
Regulation FD disclosure
Jan 12, 2026 Jan 12, 2026
10-Q Quarterly report Nov 4, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 4, 2025 Nov 4, 2025
10-Q Quarterly report Aug 6, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 6, 2025 Aug 6, 2025
8-K Current report
Shareholder vote results
Jun 18, 2025 Jun 12, 2025
10-Q Quarterly report May 1, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 1, 2025 May 1, 2025
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 28, 2025 —
DEF 14A Proxy statement Apr 28, 2025 Jun 12, 2025
8-K Current report
Other events
Mar 18, 2025 Mar 14, 2025
8-K Current report
Material agreement, Other events
Mar 13, 2025 Mar 12, 2025
424B5 Prospectus supplement Mar 13, 2025 —
424B5 Prospectus supplement Mar 12, 2025 —
S-8 Employee stock plan registration Feb 25, 2025 —
10-K Annual report Feb 25, 2025 Dec 31, 2024
8-K Current report
Results of operations
Feb 25, 2025 Feb 25, 2025
8-K Current report
Officer or director change
Jan 17, 2025 Jan 15, 2025
8-K Current report
Regulation FD disclosure
Jan 13, 2025 Jan 13, 2025
8-K Current report
Material agreement
Dec 19, 2024 Dec 16, 2024
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 13, 2024 Nov 13, 2024
8-K Current report
Officer or director change
Nov 5, 2024 Nov 1, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
8-K Current report
Shareholder vote results
Jun 18, 2024 Jun 13, 2024
10-Q Quarterly report May 8, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 8, 2024 May 8, 2024
ARS Annual report to shareholders Apr 26, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 13, 2024
8-K Current report
Material agreement, New debt, Regulation FD disclosure
Apr 23, 2024 Apr 19, 2024
8-K Current report
Other events
Mar 5, 2024 Mar 5, 2024
8-K Current report
Material agreement, Other events
Mar 1, 2024 Feb 29, 2024
424B5 Prospectus supplement Mar 1, 2024 —
424B5 Prospectus supplement Feb 29, 2024 —
S-3ASR Automatic shelf registration Feb 29, 2024 —
S-8 Employee stock plan registration Feb 27, 2024 —
10-K Annual report Feb 27, 2024 Dec 31, 2023
8-K Current report
Results of operations
Feb 27, 2024 Feb 27, 2024
8-K Current report
Officer or director change
Jan 18, 2024 Jan 11, 2024
8-K Current report
Regulation FD disclosure
Jan 8, 2024 Jan 8, 2024
8-K Current report
Other events
Dec 11, 2023 Dec 11, 2023
EFFECT Filing Nov 21, 2023 —
CORRESP Letter to the SEC Nov 17, 2023 —
UPLOAD Letter from the SEC Nov 16, 2023 —
S-3 Shelf registration Nov 9, 2023 —
8-K Current report
Results of operations
Nov 9, 2023 Nov 9, 2023
10-Q Quarterly report Nov 9, 2023 Sep 30, 2023
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 10, 2023 Aug 10, 2023
8-K Current report
Material agreement, Other events
Aug 2, 2023 Jul 31, 2023
424B5 Prospectus supplement Aug 2, 2023 —
424B5 Prospectus supplement Jul 31, 2023 —
8-K Current report
Other events
Jul 31, 2023 Jul 31, 2023
8-K Current report
Regulation FD disclosure
Jul 25, 2023 Jul 25, 2023
8-K Current report
Shareholder vote results
Jun 27, 2023 Jun 22, 2023
8-K Current report
Regulation FD disclosure
Jun 15, 2023 Jun 15, 2023
10-Q Quarterly report May 9, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 9, 2023 May 9, 2023
ARS Annual report to shareholders Apr 26, 2023 Dec 31, 2022
DEFA14A Additional proxy material Apr 26, 2023 —
DEF 14A Proxy statement Apr 26, 2023 Dec 31, 2022
8-K Current report
Officer or director change
Apr 24, 2023 Apr 18, 2023
UPLOAD Letter from the SEC Apr 18, 2023 —
CORRESP Letter to the SEC Apr 13, 2023 —
UPLOAD Letter from the SEC Mar 30, 2023 —
S-8 Employee stock plan registration Mar 17, 2023 —
10-K Annual report Mar 17, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 13, 2023 Mar 13, 2023
8-K Current report
Material agreement
Jan 5, 2023 Jan 5, 2023
8-K Current report
Officer or director change
Dec 7, 2022 Dec 1, 2022
10-Q Quarterly report Nov 9, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 9, 2022 Nov 9, 2022
8-K Current report
Officer or director change
Oct 12, 2022 Oct 6, 2022
10-Q Quarterly report Aug 11, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 11, 2022 Aug 11, 2022
8-K Current report
Shareholder vote results
Jun 22, 2022 Jun 16, 2022
10-Q Quarterly report May 11, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 10, 2022 May 10, 2022
8-K Current report
Material agreement, Other events
May 4, 2022 May 2, 2022
424B5 Prospectus supplement May 4, 2022 —
8-K Current report
Other events
May 3, 2022 May 2, 2022
FWP Free writing prospectus May 3, 2022 —
8-K Current report
Regulation FD disclosure
May 2, 2022 May 2, 2022
424B5 Prospectus supplement May 2, 2022 —
8-K Current report
Other events
May 2, 2022 May 2, 2022
DEFA14A Additional proxy material May 2, 2022 —
DEF 14A Proxy statement May 2, 2022 Jun 16, 2022
S-8 Employee stock plan registration Mar 14, 2022 —
10-K Annual report Mar 14, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 14, 2022 Mar 14, 2022
8-K Current report
Material agreement, New debt
Feb 2, 2022 Feb 2, 2022
8-K Current report
Officer or director change
Jan 4, 2022 Dec 31, 2021
10-Q Quarterly report Nov 10, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 9, 2021 Nov 9, 2021
EFFECT Filing Nov 5, 2021 —
CORRESP Letter to the SEC Nov 3, 2021 —
UPLOAD Letter from the SEC Nov 3, 2021 —
8-K Current report
Other events
Nov 1, 2021 Nov 1, 2021
S-3 Shelf registration Nov 1, 2021 —
8-K Current report
Officer or director change
Aug 12, 2021 Aug 10, 2021
10-Q Quarterly report Aug 5, 2021 Jun 30, 2021
8-K Current report
Results of operations
Aug 5, 2021 Aug 4, 2021
8-K Current report
Shareholder vote results
Jun 22, 2021 Jun 15, 2021
8-K Current report
Other events
Jun 21, 2021 Jun 21, 2021
10-Q Quarterly report May 11, 2021 Mar 31, 2021
8-K Current report
Results of operations
May 11, 2021 May 11, 2021
DEFA14A Additional proxy material Apr 30, 2021 —
DEF 14A Proxy statement Apr 30, 2021 Jun 15, 2021
8-K Current report
Regulation FD disclosure
Apr 9, 2021 Apr 8, 2021
S-8 Employee stock plan registration Mar 31, 2021 —
10-K Annual report Mar 31, 2021 Dec 31, 2020
8-K Current report
Results of operations
Mar 31, 2021 Mar 31, 2021
8-K Current report
Material agreement, Other events
Mar 30, 2021 Mar 26, 2021
10-Q Quarterly report Nov 25, 2020 Sep 30, 2020
8-K Current report
Officer or director change
Nov 20, 2020 Nov 19, 2020
8-K Current report
Regulation FD disclosure
Nov 17, 2020 Nov 17, 2020
S-8 Employee stock plan registration Oct 20, 2020 —
8-K Current report
Bylaw or fiscal year change
Oct 20, 2020 Oct 20, 2020
424B4 Prospectus Oct 16, 2020 —
EFFECT Filing Oct 15, 2020 —
S-1MEF Filing Oct 15, 2020 —
CERT Filing Oct 15, 2020 —
SEC STAFF LETTER Filing Oct 14, 2020 —
CORRESP Letter to the SEC Oct 13, 2020 —
CORRESP Letter to the SEC Oct 13, 2020 —
8-A12B Filing Oct 13, 2020 —
CORRESP Letter to the SEC Oct 9, 2020 —
S-1/A Amended registration statement Oct 9, 2020 —
UPLOAD Letter from the SEC Oct 7, 2020 —
CORRESP Letter to the SEC Oct 6, 2020 —
CORRESP Letter to the SEC Sep 25, 2020 —
S-1 Registration statement Sep 25, 2020 —
UPLOAD Letter from the SEC Sep 24, 2020 —
DRSLTR Filing Sep 14, 2020 —
DRS/A Filing Sep 14, 2020 —
SEC STAFF LETTER Filing Sep 4, 2020 —
UPLOAD Letter from the SEC Sep 4, 2020 —
DRS/A Filing Aug 14, 2020 —
DRS Filing Aug 7, 2020 —

Showing 164 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TARS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Irvine, CA
SEC filer status
Large accelerated filer
SEC CIK
1819790

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.